Drug Profile
CX 516
Alternative Names: 1-BCP; Ampakine CX 516; AMPAlex; BDP-12; SPD 420Latest Information Update: 25 Sep 2021
Price :
$50
*
At a glance
- Originator Cortex Pharmaceuticals
- Class Piperidines
- Mechanism of Action AMPA receptor agonists; AMPA receptor antagonists; Glutamate agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Alzheimer's disease; Attention-deficit hyperactivity disorder; Autistic disorder; Mild cognitive impairment; Schizophrenia; Sleep disorders; Stroke
Most Recent Events
- 11 Oct 2004 Two studies have been added to the adverse events and Psychotic disorders therapeutic trials sections ,
- 01 Jul 2004 Phase-II clinical trials in Sleep disorders in USA (unspecified route)
- 20 Feb 2004 Data from a media release have been added to the Alzheimer's disease and Cognitive disorders therapeutic trials section